title: New immunosuppressive regimens in lung transplantation.
abstract: Survival after lung transplantation is less than 50% after 5 yrs and is limited by infection and obliterative bronchiolitis. There is, therefore, a need for new immunosuppressive regimens if we are to attempt to improve long-term survival. Several trials in lung transplantation of new immunosuppressive agents are in the planning stages. In this article, we review the experience with a new monoclonal agent (interleukin 2 (IL2) receptor antagonist) in kidney transplantation, together with the pharmacokinetic (PK) and pharmacodynamic properties and experience in transplantation in general, of the more promising of the new xenobiotic compounds (cyclosporine microemulsion, mycophenolate mofetil, tacrolimus and sirolimus). Recent novel approaches to the vexing problem of resistant lung rejection and obliterative bronchiolitis, such as the use of aerosolized cyclosporine, methotrexate, total lymphoid irradiation and phototherapy, are discussed. Finally an immunosuppressive regimen, using these new drugs in lung transplantation is suggested.
authors.affiliation: Transplantation Immunology, Dept of Cardiothoracic Surgery, Stanford University School of Medicine, CA 94305-5247, USA.
authors.forename: N
authors.initials: N
authors.lastname: Briffa
authors.forename: R E
authors.initials: RE
authors.lastname: Morris
mesh_terms: D001989:Bronchiolitis Obliterans / Q000628:therapy; D004359:Drug Therapy, Combination; D006084:Graft Rejection / Q000517:prevention & control*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology; D016040:Lung Transplantation / Q000276:immunology / Q000401:mortality
chemical_list: D007166:Immunosuppressive Agents